Overall and cause-specific mortality in patients with systemic lupus erythematosus: A meta-analysis of observational studies

Arthritis Care and Research

Volumn 66, Issue 4, 2014, Pages 608-616

  Yurkovich, Marko ^a   Vostretsova, Kateryna ^a   Chen, Wenjia ^a   Aviña Zubieta, J Antonio ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b ARTHRITIS RESEARCH CENTRE OF CANADA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CARDIOVASCULAR DISEASE; COMPARATIVE STUDY; HUMAN; INFECTION; KIDNEY DISEASE; META ANALYSIS; MORTALITY; OBSERVATIONAL STUDY; POPULATION; RISK FACTOR; STANDARDIZED MORTALITY RATIO; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

CARDIOVASCULAR DISEASES; HUMANS; INFECTION; KIDNEY DISEASES; LUPUS ERYTHEMATOSUS, SYSTEMIC; NEOPLASMS;

EID: 84890473053     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22173     Document Type: Article

References (38)

1. Alamanos Y, Voulgari PV, Siozos C, Katsimpri P, Tsintzos S, Dimou G, et al. Epidemiology of systemic lupus erythematosus in Northwest Greece 1982-2001. J Rheumatol 2003; 30: 731-5.
2. Hersh AO, Trupin L, Yazdany J, Panopalis P, Julian L, Katz P, et al. Childhood-onset disease as a predictor of mortality in an adult cohort of patients with systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2010; 62: 1152-9.
3. Urowitz MB, Gladman DD, Tom BD, Ibanez D, Farewell VT,. Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus. J Rheumatol 2008; 35: 2152-8.
4. Uramoto KM, Michet CJ Jr, Thumboo J, Sunku J, O'Fallon WM, Gabriel SE,. Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992. Arthritis Rheum 1999; 42: 46-50.
5. Borchers AT, Keen CL, Shoenfeld Y, Gershwin ME,. Surviving the butterfly and the wolf: mortality trends in systemic lupus erythematosus. Autoimmun Rev 2004; 3: 423-53.
6. Hopkinson N,. Epidemiology of systemic lupus erythematosus. Ann Rheum Dis 1992; 51: 1292-4.
7. Ward MM,. Cardiovascular and cerebrovascular morbidity and mortality among women with end-stage renal disease attributable to lupus nephritis. Am J Kidney Dis 2000; 36: 516-25.
8. Bjornadal L, Yin L, Granath F, Klareskog L, Ekbom A,. Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964-95. J Rheumatol 2004; 31: 713-9.
9. Chun BC, Bae SC,. Mortality and cancer incidence in Korean patients with systemic lupus erythematosus: results from the Hanyang lupus cohort in Seoul, Korea. Lupus 2005; 14: 635-8.
10. Jacobsen S, Petersen J, Ullman S, Junker P, Voss A, Rasmussen JM, et al. Mortality and causes of death of 513 Danish patients with systemic lupus erythematosus. Scand J Rheumatol 1999; 28: 75-80.
11. Takkouche B, Etminan M, Montes-Martinez A,. Personal use of hair dyes and risk of cancer: a meta-analysis. JAMA 2005; 293: 2516-25.
12. Bhutta AT, Cleves MA, Casey PH, Cradock MM, Anand KJ,. Cognitive and behavioral outcomes of school-aged children who were born preterm: a meta-analysis. JAMA 2002; 288: 728-37.
13. Avina-Zubieta JA, Thomas J, Sadatsafavi M, Lehman AJ, Lacaille D,. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 2012; 71: 1524-9.
14. Avina-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D,. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008; 59: 1690-7.
15. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
16. Thompson SG, Higgins JP,. How should meta-regression analyses be undertaken and interpreted? Stat Med 2002; 21: 1559-73.
17. Miller R,. The jackknife: a review. Biometrika 1974; 61: 1-15.
18. Sterne JA, Egger M,. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol 2001; 54: 1046-55.
19. Begg C, Berlin J,. Publication bias: a problem in interpreting medical data. J R Stat Soc 1988; 54: 629-34.
20. Alamanos Y, Voulgari PV, Papassava M, Tsamandouraki K, Drosos AA,. Survival and mortality rates of systemic lupus erythematosus patients in Northwest Greece: study of a 21-year incidence cohort. Rheumatology (Oxford) 2003; 42: 1122-3.
21. Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Gladman DD, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum 2006; 54: 2550-7.
22. Bernatsky S, Clarke A, Gladman DD, Urowitz M, Fortin PR, Barr SG, et al. Mortality related to cerebrovascular disease in systemic lupus erythematosus. Lupus 2006; 15: 835-9.
23. Mok CC, Kwok CL, Ho LY, Chan PT, Yip SF,. Life expectancy, standardized mortality ratios, and causes of death in six rheumatic diseases in Hong Kong, China. Arthritis Rheum 2011; 63: 1182-9.
24. Mok CC, To CH, Ho LY, Yu KL,. Incidence and mortality of systemic lupus erythematosus in a Southern Chinese population, 2000-2006. J Rheumatol 2008; 35: 1978-82.
25. To CH, Mok CC, Tang SS, Ying SK, Wong RW, Lau CS,. Prognostically distinct clinical patterns of systemic lupus erythematosus identified by cluster analysis. Lupus 2009; 18: 1267-75.
26. Nived O, Bengtsson A, Jonsen A, Sturfelt G, Olsson H,. Malignancies during follow-up in an epidemiologically defined systemic lupus erythematosus inception cohort in Southern Sweden. Lupus 2001; 10: 500-4.
27. Bernatsky S, Ramsey-Goldman R, Clarke AE,. Malignancy risk in systemic lupus: recent research and ongoing challenges. Curr Rheumatol Rev 2008; 4: 59-62.
28. Ward MM, Pyun E, Studenski S,. Long-term survival in systemic lupus erythematosus: patient characteristics associated with poorer outcomes. Arthritis Rheum 1995; 38: 274-83.
29. Manger K, Manger B, Repp R, Geisselbrecht M, Geiger A, Pfahlberg A, et al. Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus. Ann Rheum Dis 2002; 61: 1065-70.
30. Goodson NJ, Solomon DH,. The cardiovascular manifestations of rheumatic diseases. Curr Opin Rheumatol 2006; 18: 135-40.
31. Nikpour M, Urowitz MB, Gladman DD,. Premature atherosclerosis in systemic lupus erythematosus. Rheum Dis Clin North Am 2005; 31: 329-54.
32. Karp I, Abrahamowicz M, Fortin PR, Pilote L, Neville C, Pineau CA, et al. Recent corticosteroid use and recent disease activity: independent determinants of coronary heart disease risk factors in systemic lupus erythematosus? Arthritis Rheum 2008; 59: 169-75.
33. Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2399-406.
34. Bernatsky S, Ramsey-Goldman R, Rajan R, Boivin JF, Joseph L, Lachance S, et al. Non-Hodgkin's lymphoma in systemic lupus erythematosus. Ann Rheum Dis 2005; 64: 1507-9.
35. Mellemkjaer L, Andersen V, Linet MS, Gridley G, Hoover R, Olsen JH,. Non-Hodgkin's lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus. Arthritis Rheum 1997; 40: 761-8.
36. Agudelo CA, Schumacher HR, Glick JH, Molina J,. Non-Hodgkin's lymphoma in systemic lupus erythematosus: report of 4 cases with ultrastructural studies in 2. J Rheumatol 1981; 8: 69-78.
37. Bernatsky S, Ramsey-Goldman R, Labrecque J, Joseph L, Boivin JF, Petri M, et al. Cancer risk in systemic lupus: an updated international multi-centre cohort study. J Autoimmun 2013; 42: 130-5.
38. Higgins JP, Thompson SG, Deeks JJ, Altman DG,. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-60.